Manoj Kumar Mishra

Dr. Manoj Kumar Mishra

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2016 in International Journal of Current Pharmaceutical Research
Verified
Journal Article
Open access
PDF file
SYSunil Kumar Yadav
Sunil Kumar Yadav
MMManoj Kumar Mishra
Manoj Kumar Mishra
ATAnupamaa Tiwari
Anupamaa Tiwari
ASAshutosh Shukla
Ashutosh Shukla
Emulgel is used to treat aches and pains caused by colds, headaches, muscle aches, backaches, arthritis and other conditions and injuries. The patient adherence to topical formulations is significant in relation to chronic skin diseases, like fungal infections, acne, psoriasis. Emulgel is one of the recent technology in NDDS used topically having characteristics of dual control release i.e. emulsion as well as gel. Emulgels have emerged as one of the most interesting topical delivery systems as it has dual release control system i.e. gel and emulsion. When gel and emulsion are used in combined form, the dosage form are referred as emulgel.

30 May 2019 in GSC Biological and Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
RSRajat Srivastava
Rajat Srivastava
MMManoj Kumar Mishra
Manoj Kumar Mishra
APAmit Kumar Patel
Amit Kumar Patel
ASAbhishek Singh
Abhishek Singh
KKKrishna Kushwaha
Krishna Kushwaha

1 January 2016 in Journal of Applied Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
SSShipra Sonekar
Shipra Sonekar
MMManoj Kumar Mishra
Manoj Kumar Mishra
APAnil Kumar Patel
Anil Kumar Patel
SNSuresh Kumar Nair
Suresh Kumar Nair
CSChandra Shekhar Singh
Chandra Shekhar Singh
ASAmit Kumar Singh
Amit Kumar Singh

23 July 2009 in AAPS PharmSciTech
Verified
Journal Article
Closed access
PDF file
MMManoj Kumar Mishra
Manoj Kumar Mishra
DRDebajyoti Ray
Debajyoti Ray
BBBhakti B. Barik
Bhakti B. Barik

1 March 2021 in ASSAY and Drug Development Technologies
Verified
Journal Article
Closed access
APAmit Kumar Patel
Amit Kumar Patel
MMManoj Kumar Mishra
Manoj Kumar Mishra
JGJitendra Gupta
Jitendra Gupta
SGSaurav Ghoshal
Saurav Ghoshal
RGReena Gupta
Reena Gupta
KKKrishna Kushwaha
Krishna Kushwaha
In this present study, floating microspheres of repaglinide were successfully fabricated by the solvent evaporation technique with varying ratios of guar gum, hydroxypropyl methylcellulose, and ethylcellulose with polyvinyl alcohol. Microspheres were characterized by production yield, particle size, in vitro buoyancy, entrapment efficiency, in vitro drug release, and in vivo floating behavior in albino rats. The formulation process was optimized for stirring speed (X1) and concentration of polymer ratio (X2) on dependent variables such as percentage entrapment efficiency, percentage yield, in vitro buoyancy, and percentage of drug release by the 32 factorial Design-Expert® 12, trial version, software. The optimized formulation was characterized by Fourier transform infrared spectroscopy, powder X-ray diffraction, differential scanning calorimetry, and scanning electron microscopy and was successfully formulated with the highest percentage of cumulative drug release (94.26 ± 3.10), entrapment efficiency (74.70% ± 2.16%), and particle size (50.34 ± 3.67 μm) and remains buoyant for 24 h in simulated gastric fluid (0.1N HCL) with high in vitro buoyancy percent (84.90 ± 2.88). When the drug–polymer solution of dichloromethane and ethanol is dropped in polyvinyl alcohol solution, it leads to the formation of a shell and produces cavities, creating the buoyant nature of floating microspheres. X-ray imaging indicates the uniform distribution and buoyant nature of microspheres in the gastric fluid for a 10-h period.

1 March 2024 in Infectious Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
RSRajat Srivastava
Rajat Srivastava
ARAjay Kumar Singh Rawat
Ajay Kumar Singh Rawat
MMManoj Kumar Mishra
Manoj Kumar Mishra
APAmit Kumar Patel
Amit Kumar Patel
: Infections caused by fungi can be mildly bothersome or fatal, causing life-threatening conditions or even death. Antifungal drugs have used synthetic chemicals, organic compounds, and phytoconstituents in their formulations to treat fungal infections. Research into novel antifungal drugs has progressed more rapidly than into antibacterial treatments. This can be attributed to the low resistance of fungal infections to antifungal bioactivities and the relatively low incidence of these diseases. Carrier systems based on nanotechnology have generated much interest recently because of the incredible potential of these systems. By using nanoarchitecture as a better carrier and drug delivery system (DDS), we can have greater antifungal effectiveness, bioavailability, targeted action, and less cytotoxicity, a development made possible using nanotechnology. This review discusses various nanocarrier-based technologies in addition to other nanotechnological methods. These include liposomes, transfersomes, ethosomes, niosomes, dendrimers, polymeric nanoparticles, polymer nanocomposites, metallic nanoparticles, carbon nanomaterials, etc. : This review focused on general information regarding fungi infections, different antifungal agent types and mechanisms of action, and an overview of formulation strategies such as nanotechnology systems, which are frequently researched for antifungal therapies. : We concluded that new drug delivery systems are crucial to delivering antifungal medicines to their target site with the optimum concentration. The researchers also concentrated on these innovative drug delivery systems, which primarily focus on regulating and maintaining the release of antifungal drugs.